Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study

Fig. 2Fig. 2Fig. 2Fig. 2Fig. 2

Sensitivity and subgroup analyses of comparative risk for cardiovascular events between SGLT2 inhibitors. BMI body mass index, CI confidence interval, eGFR estimated glomerular filtration rate, HR hazard ratio, LDL low-density lipoprotein, SIPTW stabilized inverse probability of treatment weighting, SMRW standardized mortality ratio weighting, UACR urine albumin–creatinine ratio

Back to article page